A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

(2014) P. J. Hesketh et al.   ANNALS OF ONCOLOGY

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy

(2014) R. J. Gralla et al.   ANNALS OF ONCOLOGY

Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial

(2013) Ralph Boccia et al.   SUPPORTIVE CARE IN CANCER

Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone

(2013) Corinna Lanzarotti et al.   SUPPORTIVE CARE IN CANCER

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)

(2012) M. Aapro et al.   ANNALS OF ONCOLOGY

Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects

(2012) Marigo Stathis et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting

(2012) Camilo Rojas et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

(2011) Ethan Basch et al.   JOURNAL OF CLINICAL ONCOLOGY

Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy

(2010) M. Aapro et al.   ANNALS OF ONCOLOGY

Update and new trends in antiemetic therapy: the continuing need for novel therapies

(2010) P. Feyer et al.   ANNALS OF ONCOLOGY

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

(2010) F. Roila et al.   ANNALS OF ONCOLOGY